Cell Therapeutics EVP Louis A. Bianco Sells 10,000 Shares (CTIC)
Cell Therapeutics (NASDAQ:CTIC) EVP Louis A. Bianco unloaded 10,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $2.97, for a total value of $29,700.00. Following the sale, the executive vice president now directly owns 802,897 shares in the company, valued at approximately $2,384,604. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Cell Therapeutics (NASDAQ:CTIC) traded down 1.32% during mid-day trading on Friday, hitting $2.98. The stock had a trading volume of 1,185,080 shares. Cell Therapeutics has a 52-week low of $0.97 and a 52-week high of $4.25. The stock’s 50-day moving average is $2.91 and its 200-day moving average is $2.94. The company’s market cap is $423.6 million.
Cell Therapeutics (NASDAQ:CTIC) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.10 million. On average, analysts predict that Cell Therapeutics will post $-0.60 earnings per share for the current fiscal year.
A number of research firms have recently commented on CTIC. Analysts at Ladenburg Thalmann initiated coverage on shares of Cell Therapeutics in a research note on Thursday, May 22nd. They set a “buy” rating and a $6.00 price target on the stock. Analysts at WallachBeth Capital initiated coverage on shares of Cell Therapeutics in a research note on Wednesday, March 19th. They set a “hold” rating and a $4.50 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.83.
Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.